- Home
- PSNYW vs BCYC Comparison
PSNYW vs BCYC Comparison
Compare PSNYW & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNYW | BCYC |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | Sweden | United Kingdom |
| Employees | 1686 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.9M | 310.7M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | PSNYW | BCYC |
|---|---|---|
| Price | $2.68 | $3.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $13.90 |
| AVG Volume (30 Days) | 5.5K | ★ 547.6K |
| Earning Date | 03-06-2025 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,034,261,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $79.49 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.14 | $3.95 |
| 52 Week High | $7.50 | $9.18 |
Technical Indicators
Market Signals| Indicator | PSNYW | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 42.09 | 34.69 |
| Support Level | $2.45 | N/A |
| Resistance Level | $3.50 | $5.31 |
| Average True Range (ATR) | 0.23 | 0.19 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 23.68 | 5.45 |
Price Performance
Historical ComparisonAbout PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)
Polestar Automotive Holding UK PLC is a pure play, premium electric car brand, designing performance cars engineered to excite consumers and drive change. It believes that it defines market standards in design, innovation and sustainability. It is determined to improve society by accelerating the shift to sustainable mobility. The company conducts its business as one operating segment with primary commercial operations in Europe, North America, Asia Pacific and various importer markets. The company generates majority of revenue from United Kingdom.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.